Migraine and anti-phospholipid antibodies.
Anti-phospholipid antibodies (APA), initially described with SLE, have in recent years received much attention because of an associated increased risk of thrombo-embolic disease, recurrent abortion and thrombocytopenia. Although commonly seen with SLE or other collagen vascular diseases, the antibodies frequently occur in the absence of any such disease. Neurologic complications include transient or permanent ischemic episodes, migraine or related phenomena, myelopathy and a Guillain-Barré type syndrome. In this report we describe the presenting features and clinical course of six patients with anti-phospholipid antibodies where migraine was an early and prominent symptom. All six patients, however, were recognized only after a second more serious event had occurred. As this entity becomes more widely recognized and better treatments evolve an earlier diagnosis of patients with migraine as the only manifestation of APA may prevent the development of other serious complications.
Shuaib
A
A
Barklay
L
L
Lee
M A
MA
Suchowersky
O
O
D000328:Adult; D000906:Antibodies / Q000032:analysis*; D001777:Blood Coagulation; D005260:Female; D006801:Humans; D008875:Middle Aged; D008881:Migraine Disorders / Q000097:blood / Q000276:immunology* / Q000503:physiopathology; D010743:Phospholipids / Q000097:blood / Q000276:immunology*
D000906:Antibodies; D010743:Phospholipids